Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to slow advanced breast cancer

NCT ID NCT07195227

Recruiting now Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs, camizestrant and ribociclib, together in people with advanced hormone receptor-positive (HR+) breast cancer. The goal is to see if the combination can delay cancer growth better than current treatments. About 150 adults who have already received hormone therapy for at least 5 years will take part. The main focus is on how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
camizestrant and ribociclib
What this could lead to
If successful, this combination could offer a new treatment option for advanced HR+ breast cancer, potentially delaying disease progression.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not confirm effectiveness. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HORMON RECEPTOR POSITIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Beata Maria Ana

    ACTIVE_NOT_RECRUITING

    Madrid, Spain

  • H Quirónsalud Sagrado Corazón

    ACTIVE_NOT_RECRUITING

    Seville, Spain

  • HU Virgen de las Nieves

    ACTIVE_NOT_RECRUITING

    Granada, Spain

  • HUAV Valencia

    RECRUITING

    Valencia, Spain

  • Hospital Clínic Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital Dexeus

    RECRUITING

    Barcelona, Spain

  • Hospital General Universitario Dr. Balmis

    ACTIVE_NOT_RECRUITING

    Alicante, Spain

  • Hospital Ramón y Cajal

    ACTIVE_NOT_RECRUITING

    Madrid, Spain

  • Hospital Regional Universitario de Málaga

    ACTIVE_NOT_RECRUITING

    Málaga, Spain

  • Hospital Universitario de Jerez de la Frontera

    RECRUITING

    Jerez de la Frontera, Spain

  • Hospital Universitario de León

    RECRUITING

    León, Spain

  • Hospital Universitario y Politécnico de La Fe

    ACTIVE_NOT_RECRUITING

    Valencia, Spain

  • IVO - Instituto Valenciano de Oncología

    RECRUITING

    Valencia, Spain

  • Institut Català d'Oncologia Girona - ICO Girona

    RECRUITING

    Girona, Spain

  • Sant Joan de Reus

    RECRUITING

    Reus, Spain

  • Städtisches Klinikum Dessau

    ACTIVE_NOT_RECRUITING

    Dessau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.